Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC

Dr Francesco Sclafani - Institut Jules Bordet, Brussels, Belgium
The combination of regorafenib, nivolumab and SCRT shows promising efficacy as neoadjuvant therapy for locally advanced RC ( Dr Francesco Sclafani - Institut Jules Bordet, Brussels, Belgium )
25 Jul 2024

Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC

Prof Michel Ducreux - Gustave Roussy Cancer Centre, Paris, France
Trifluridine/tipiracil followed by regorafenib can be an effective treatment sequence in pretreated mCRC ( Prof Michel Ducreux - Gustave Roussy Cancer Centre, Paris, France )
24 Jul 2024

Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients

Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea
Durvalumab, gemcitabine and cisplatin continue to show clinically meaningful long-term survival in biliary tract cancer patients ( Dr Do-Youn Oh - Seoul National University Hospital, Seoul, Korea )
15 Jul 2024

Research highlights in gastrointestinal tumours

Dr Jesus Fabregas - Memorial Cancer Institute, Miami, USA
Research highlights in gastrointestinal tumours ( Dr Jesus Fabregas - Memorial Cancer Institute, Miami, USA )
12 Jul 2024

Updates from ASCO 2024 in gastrointestinal tumours

Dr Samuel Kareff - University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, USA
Updates from ASCO 2024 in gastrointestinal tumours ( Dr Samuel Kareff - University of Miami Sylvester Comprehensive Cancer Center/Jackson Memorial Hospital, Miami, USA )
12 Jul 2024

Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC

Prof David Tougeron - Poitiers University Hospital, Poitiers, France
Pembrolizumab combined with xelox and bevacizumab shows higher efficacy than standard therapeutic regimen in mCRC ( Prof David Tougeron - Poitiers University Hospital, Poitiers, France )
9 Jul 2024

Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer

Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy
Paclitaxel and ramucirumab switch maintenance therapy prolongs survival in HER2-negative advanced GEJ cancer ( Dr Giovanni Randon - The National Cancer Institute of Milan, Milano, Italy )
9 Jul 2024

Administering systemic chemotherapy improves survival for patients with resectable CRCLM

Dr Giacomo Bregni - Francis Crick Institute, London, England
Administering systemic chemotherapy improves survival for patients with resectable CRCLM ( Dr Giacomo Bregni - Francis Crick Institute, London, England )
9 Jul 2024

Immunotherapy significantly increases the number of patients free from bowel cancer

Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK
Immunotherapy significantly increases the number of patients free from bowel cancer ( Dr Kai-Keen Shiu - UCL Cancer Institute, London, UK )
14 Jun 2024

ASCO 2024: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2024: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )
4 Jun 2024

Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC

Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA
Nivolumab plus ipilimumab shows clinical benefit as first-line treatment for centrally confirmed MSI-H/dMMR mCRC ( Prof Heinz-Josef Lenz - Keck School of Medicine of USC, Los Angeles, USA )
2 Jun 2024

Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures

Prof Antoine Italiano - Institute Bergonié, Bordeaux, France
Avelumab combined with regorafenib shows improved outcome in solid tumours with tertiary lymphoid structures ( Prof Antoine Italiano - Institute Bergonié, Bordeaux, France )
24 Apr 2024